Rabies Vaccine(Vero Cell)for Human Use (Aleph Biomedical)

In the population aged 10-60 years, three consecutive production batches of vaccine were administered. Blood was drawn from all subjects before the first dose, 14 days after the first dose, and 14 days after the full course of vaccination. Blood was drawn from the first 210 subjects 12 months later to test rabies virus neutralizing antibodies and analyze the immunogenicity at the above time points. All AEs within 30 days from the first dose to the full course of vaccination and all SAEs within 6 months were collected to evaluate safety.